Table 1.
Baseline Characteristics and Transplant Outcomes
| Baseline Characteristics | No IFD n=176 | IFD n=29 | All Patients, No. (%) (n = 205) |
|---|---|---|---|
| Demographics | |||
| Age, median (range) | 57 (19 – 76) | 57 (21 – 77) | 57 (19 – 77) |
| Male sex, no. (%) | 102 (58) | 19 (66) | 121 (59) |
| Underlying Disease | |||
| AML, no. (%) | 64 (36) | 17 (59) | 81 (40) |
| MDS/MPN, no. (%) | 42 (24) | 4 (14) | 46 (22) |
| NHL, no. (%) | 21 (12) | 3 (10) | 24 (12) |
| ALL, no. (%) | 17 (10) | 4 (14) | 21 (10) |
| HL, no. (%) | 8 (5) | 1 (3) | 9 (4) |
| Other acute leukemia | 9 (5) | 0 (0) | 9 (4) |
| SAA, no. (%) | 4 (2) | 1 (3) | 5 (2) |
| Hemoglobinopathy, no. (%) | 4 (2) | 0 (0) | 4 (2) |
| CML, no. (%) | 3 (2) | 0 (0) | 3 (1) |
| HLH, no. (%) | 2 (1) | 0 (0) | 2 (1) |
| Autoimmune, no. (%) | 1 (0.6) | 0 (0) | 1 (0.5) |
| Prior HCT | |||
| Allogeneic | 12 (7) | 5 (17) | 17 (8) |
| Autologous | 11 (6) | 1 (3) | 12 (6) |
| Graft | |||
| Bone Marrow | 93 (53) | 12 (41) | 105 (51) |
| Peripheral blood | 83 (47) | 17 (59) | 100 (49) |
| Conditioning Intensity | |||
| Myeloablative | 41 (23) | 10 (34) | 51 (25) |
| RIC / NMA | 135 (77) | 19 (66) | 154 (75) |
| Transplant Outcomes | No IFD n=176 | IFD n=29 | All Patients, No. (%) (n = 205) |
| Acute GVHD | 92 (52) | 13 (45) | 105 (51) |
| GVHD Grade | |||
| Grade-I | 50 (54) | 10 (77) | 60 (57) |
| Grade II | 34 (37) | 3 (23) | 37 (35) |
| Grade III | 8 (9) | 0 (0) | 8 (8) |
| Tx ≥ 1 mg/kg Corticosteroids | 53 (58) | 8 (62) | 61 (58) |
| CRS Diagnosis | 92 (52) | 18 (62) | 110 (54) |
| Tocilizumab | 20 (11) | 9 (31) | 29 (14) |